Medullary thyroid microcarcinoma: A population-level analysis of 310 patients

Cancer

Volumn 118, Issue 3, 2012, Pages 620-627

  Kazaure, Hadiza S ^a   Roman, Sanziana A ^a   Sosa, Julie A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

And End Results; Epidemiology; lymph node metastases; medullary thyroid cancer; medullary thyroid microcarcinoma; prognosis; Surveillance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; LOBECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDULLARY THYROID MICROCARCINOMA; MULTIPLE CANCER; OVERALL SURVIVAL; POPULATION RISK; PRIORITY JOURNAL; SURVIVAL RATE; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

AGED; CARCINOMA, MEDULLARY; CONNECTICUT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; NEOPLASM RECURRENCE, LOCAL; SEER PROGRAM; THYROID NEOPLASMS;

EID: 84856233297     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26283     Document Type: Article

References (38)

1. Pitt SC, Moley JF,. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol. 2010; 37: 567-579.
2. Raffel A, Cupisti K, Krausch M, Wolf A, Schulte K, Roher H,. Incidentally found medullary thyroid cancer: treatment rationale for small tumors. World J Surg. 2004; 28: 397-401.
3. Roman S, Lin R, Sosa JA,. Prognosis of medullary thyroid carcinoma. Cancer. 2006; 107: 2134-2142.
4. Scollo C, Baudin E, Travagli J, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003; 88: 2070-2075.
5. Sakorafas GH, Friess H, Peros G,. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer. 2008; 15: 871-884.
6. Machens A, Hauptmann S, Dralle H,. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg. 2008; 95: 586-591.
7. Bumming P, Ahlman H, Nilsson B, Nilsson O, Wangberg B, Jansson S,. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma? Langenbecks Arch Surg. 2008; 393: 699-703.
8. Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007; 33: 493-497.
9. Kloos RT, Eng C, Evans DB, et al. Medullary Thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009; 19: 565-612.
10. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak KDS,. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010; 39: 775-783.
11. Baloch ZW, LiVolsi VA,. Microcarcinoma of the thyroid. Adv Anat Pathol. 2006; 13: 69-75.
12. Ogilvie JB, Patel KN, Heller KS,. Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well-differentiated thyroid microcarcinomas. Surgery. 2010; 148: 1222-1227.
13. Borget I, De Pouvourville G, Schlumberger M,. Calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab. 2007; 92: 425-427.
14. Valle LA, Kloos RT,. The prevalence of occult medullary thyroid carcinoma at autopsy. J Clin Endocrinol Metab. 2011; 96: E109-E113.
15. Hamy A, Pessaux P, Mirallie E, et al. Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol. 2005; 31: 774-777.
16. Beressi N, Campos JM, Beressi JP, et al. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of 80 cases. Thyroid. 1998; 8: 1039-1044.
17. Gimm O, Ukkat J, Dralle H,. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg. 1998; 22: 562-568.
18. Moley JF, DeBenedetti MK,. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999; 229: 880-887; discussion 887- 888.
19. Pillarisetty V, Katz S, Ghossein R, Tuttle R, Shaha A,. Micromedullary thyroid cancer: how micro is truly micro? Ann Surg Oncol. 2009; 16: 2875-2881.
20. Peix JL, Braun P, Saadat M, Berger N, El Khazen M, Mancini F,. Occult micro medullary thyroid carcinoma: therapeutic strategy and follow-up. World J Surg. 2000; 24: 1373-1376.
21. Dotzenrath C, Goretzki PE, Cupisti K, et al. Is there any consensus in diagnostic and operative strategy with respect to medullary thyroid cancer? Langenbecks Arch Surg. 2001; 386: 47-52.
22. National Cancer Institute, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program. SEER brochure. Accessed February, 2011.
23. Greene F, Compton C, Frtiz A, Shah J, Winchester D, eds. AJCC Cancer Staging Atlas. New York: Springer; 2006.
24. Akobeng AK,. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr. 2007; 96: 487-491.
25. Davies L, Welch HG,. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295: 2164-2167.
26. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009; 18: 784-791.
27. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM,. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011; 21: 231-236.
28. Hodgson N, Button J, Solorzano C,. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004; 11: 1093-1097.
29. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM,. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery. 2010; 148: 1147-1153.
30. Bernet V,. Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab. 2010; 95: 3586-3592.
31. van Heurn LWE, Schaap C, Sie G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg. 1999; 34: 568-571.
32. Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 2001; 130: 1044-1049.
33. Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL,. Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope. 2005; 115: 1445-1450.
34. Machens A, Schneyer U, Holzhausen H, Dralle H,. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005; 90: 2029-2034.
35. Miccoli P, Minuto MN, Ugolini C, et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer. 2007; 14: 1099-1105.
36. Panigrahi B, Roman S, Sosa J., Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol. 2010; 17: 1490-1498.
37. Henry J, Denizot A, Puccini M, et al. Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J Surg. 1998; 22: 752-757.
38. Parks M, Rosebraugh C,. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010; 362: 774-777.